Evidence map›Paper›PMID 38184822›Full record

ArticleBioengineered2024

Establishment and characterization of a highly metastatic hepatocellular carcinoma cell line.

Jiacheng Huang, Mengqing Sun, Menglan Wang, Anning Yu, Huilin Zheng, Chiwen Bu, Jie Zhou, Yu Zhang, Yiting Qiao, Zhenhua Hu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jiacheng HuangDepartment of Hepatobiliary and Pancreatic Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, China.
Mengqing SunSchool of Medicine, Zhejiang University, Hangzhou, China.
Menglan WangSchool of Medicine, Zhejiang University, Hangzhou, China.
Anning YuDepartment of Hepatobiliary and Pancreatic Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, China.
Huilin ZhengSchool of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, China.
Chiwen BuDepartment of General Surgery, People's Hospital of Guanyun County, Lianyungang, China.
Jie ZhouDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yu ZhangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yiting QiaoJinan Microecological Biomedicine Shandong Laboratory, Jinan, China.
Zhenhua HuDepartment of Hepatobiliary and Pancreatic Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, China.ORCID 0000-0002-8636-0757
Affiliated Hospital of Hangzhou Normal University · CNFirst Affiliated Hospital Zhejiang University · CNJingning County People's Hospital · CNZhejiang University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of alcohol-related hepatocellular carcinoma (HCC) has been increasing during the last decade. Cancer research requires cell lines suitable for both

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCell CountCell LineHumansSorafenibSorafenibcell lineHepatocellular carcinomametastasisprimary culturexenograft

Identifiers

PMID38184822
PMCPMC10773622
OpenAlexW4390651673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.